IVVD Stock Overview

A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. More details

IVVD fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 97.6% below our estimate of its fair value

Earnings are forecast to grow 52.3% per year

Earnings have grown 1.9% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Has less than 1 year of cash runway

Does not have a meaningful market cap ($63M)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Invivyd

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Key Takeaways The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs. Efforts to engage with the scientific community and regulators may restore trust, enhancing future earnings and market potential.

View narrative

US$6.60

91.1% undervalued

173.47%

Revenue growth p.a.

8 days ago

View Invivyd Community

Invivyd, Inc. Competitors

Prelude Therapeutics

NasdaqGS:PRLD

US$44.9m

Pyxis Oncology

NasdaqGS:PYXS

US$65.9m

Xilio Therapeutics

NasdaqGS:XLO

US$35.9m

Zentalis Pharmaceuticals

NasdaqGM:ZNTL

US$89.8m

Price History & Performance

Summary of share price highs, lows and changes for Invivyd
Historical stock prices
Current Share Price	US$0.59
52 Week High	US$2.74
52 Week Low	US$0.35
Beta	0.41
1 Month Change	14.32%
3 Month Change	-70.44%
1 Year Change	-76.87%
3 Year Change	-77.10%
5 Year Change	n/a
Change since IPO	-97.20%

Recent News & Updates

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Apr 23 The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs.

Recent updates

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19

Shareholder Returns

	IVVD	US Biotechs	US Market
7D	-7.1%	-7.7%	1.2%
1Y	-76.9%	-13.5%	7.7%

Return vs Industry: IVVD underperformed the US Biotechs industry which returned -13.5% over the past year.

Return vs Market: IVVD underperformed the US Market which returned 7.7% over the past year.

Price Volatility

Is IVVD's price volatile compared to industry and market?
IVVD volatility
IVVD Average Weekly Movement	23.0%
Biotechs Industry Average Movement	11.8%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	4.1%

Stable Share Price: IVVD's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: IVVD's weekly volatility has decreased from 34% to 23% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2020	100	Bill Duke	invivyd.com

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19.

Invivyd, Inc. Fundamentals Summary

How do Invivyd's earnings and revenue compare to its market cap?
IVVD fundamental statistics
Market cap	US$63.41m
Earnings (TTM)	-US$169.92m
Revenue (TTM)	US$25.38m

2.8x

P/S Ratio

-0.4x

P/E Ratio

Is IVVD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVVD income statement (TTM)
Revenue	US$25.38m
Cost of Revenue	US$1.62m
Gross Profit	US$23.77m
Other Expenses	US$193.69m
Earnings	-US$169.92m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.42
Gross Margin	93.63%
Net Profit Margin	-669.42%
Debt/Equity Ratio	0%

How did IVVD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 19:22
End of Day Share Price	2025/05/07 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Invivyd, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason Kolbert	D. Boral Capital LLC.
Patrick Trucchio	H.C. Wainwright & Co.
Michael Yee	Jefferies LLC

IVVD Stock Overview

Rewards

Risk Analysis

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Invivyd, Inc. Competitors

NasdaqGS:PRLD

US$44.9m

NasdaqGS:PYXS

US$65.9m

NasdaqGS:XLO

US$35.9m

NasdaqGM:ZNTL

US$89.8m

Price History & Performance

Recent News & Updates

Invivyd Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Invivyd, Inc. Auditor Raises 'Going Concern' Doubt

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA™? (Pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Recent updates

Invivyd Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Invivyd, Inc. Auditor Raises 'Going Concern' Doubt

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA™? (Pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Invivyd, Inc. Announces Resignation of Sara Cotter from the Board of Directors

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Invivyd, Inc. Appoints Sara Cotter to Board of Directors

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd, Inc. Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd, Inc. Announces Executive Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Invivyd Announces Board Changes

Invivyd, Inc. Announces Executive Changes

Invivyd appoints interim CFO, makes headcount changes

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Adagio Therapeutics GAAP EPS of -$0.47